February 25, 2022 5:01pm

We have all experienced over-reactions, February has been such a month

Pre-open indications: 5 Hits and 4 Miss

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

The week in review …

 

The Dow closed UP +834.92 points (+2.51%); the S&P closed UP +95.95 points (+2.24%) while the Nasdaq closed UP +221.04 points (+1.64%)

 

Henry’omics:

Indexes climbed Friday, building on Thursday’s rally, as investors continued to assess the financial risks stemming from Russia’s invasion of Ukraine.

The Nasdaq is still in correction, or down at least 10% from its record high. The Dow and S&P 500 are just outside of correction territory.

 

Economic data Docket: the core personal consumption expenditures price index, the Fed’s primary inflation gauge, rose 5.2% from a year ago, the Commerce Department reported. Economists expected a 5.1% print.

 

RegMed Investors’ (RMi) pre-open: “turning or burning - the sector correction beyond the invasion of Ukraine. Yesterday, Thursday had the Nasdaq turning a 3.5% loss into 3.3% gain – this isn’t the end of revolutions” …  https://www.regmedinvestors.com/articles/12316

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Friday opened negative at 9 up/21 downs, 4 flats and 1 acquired, flipped positive at the mid-day at 17/15, 2 flats and 1 acquired, ending with a positive close of 23/8, 3 flats and 1 acquired;
  • Thursday opened neutral at 16 up/16 downs, 2 flats and 1 acquired, flipped positive at the mid-day at 25/8, 1 flat 1 acquired, ending with a positive close of 27/7 and 1 acquired;
  • Wednesday opened positive at 17 up/16 downs, 1 flat and 1 acquired, strayed negative at the mid-day at 10/24 1 acquired, ending with a negative close of 8/26 and 1 acquired;
  • Tuesday opened negative at 3 up/29 downs, 2 flats and 1 acquired, stayed negative at the mid-day at 9/22, 3 flats and 1 acquired, ending with a negative close of 7/25, 2 flats and 1 acquired;
  • Monday was a holiday

 

Pre-open Indications: 5 Hits <Biostage (OTCQB: BSTG -$0.00), bluebird bio (BLUE $0.00), UniQure NV (QURE +$0.83), CRISPR Therapeutics (CRSP +$2.57), Sangamo Therapeutics (SGMO +$0.19)> 4 Miss < Editas Medicine (EDIT +$1.04), Sage Therapeutics (SAGE +$1.94), Global Blood Therapeutics (GBT -$0.36) ReNeuron (RENE.L +$1.00)>  

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … added (MESO) and (QURE) today

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Friday closing flat with 70 shares traded after Thursday with the shares dumping -$0.67 on 1,259 shares traded after “sudden” volume on Wednesday +$0.20 with 3,070 shares traded after 12 p.m. following Tuesday’s 11 a.m. of 4,225 shares traded popping the stock +$0.70

 

Key Metrics:

  • Friday - Sector volume was LOW with 6 of the 23-upside having higher than the 3-month average volume with LOW volume of 0 of 8-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday   the IBB closed up +1.36% and XBI closed up +0.90%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -2.73 points or -9% at 27.59

 

Jumping with share pricing momentum (10 of xx):

  • Intellia Therapeutics (NTLA +$8.90 after Thursday’s +$7.41, Wednesday’s -$4.14 and Tuesday’s -$2.33),
  • CRISPR Therapeutics (CRSP +$2.57 after Thursday’s +$3.91, Wednesday’s -$2.41 and Tuesday’s -$2.63),
  • Sage Therapeutics (SAGE +$1.94 after Thursday’s +$2.10 and Wednesday’s -$1.43),
  • Editas Medicine (EDIT +$1.04 after Thursday’s +$1.45, Wednesday’s -$0.61 and Tuesday’s -$0.19),
  • ReNeuron (RENE.L +$1.00 after Thursday’s -$3.00, Wednesday’s +$1.50 and Tuesday’s -$1.50),
  • Fate Therapeutics (FATE +$0.98 after Thursday’s +$2.12 and Wednesday’s -$1.31),
  • uniQure NV (QURE +$0.83),
  • AxoGen (AXGN +$0.45),
  • Vericel (VCEL +$0.34 after Thursday’s +$6.70, Wednesday’s -$1.10 and Tuesday’s -$1.62),
  • Sangamo Therapeutics (SGMO +$0.19),

Hammered in today’s market (8 of 8):

  • Ionis Pharmaceuticals (IONS -$0.71),
  • Ultragenyx (RARE -$0.37 after Thursday’s +$3.03, Wednesday’s -$2.13 and Tuesday’s +$0.21),
  • Global Blood Therapeutics (GBT -$0.36 after Thursday’s +$1.42, Wednesday’s -$2.44 and Tuesday’s -$1.30),
  • Chinook Therapeutics (KDNY -$0.31),
  • Solid Biosciences (SLDB -$0.0574),
  • Brainstorm Cell Therapeutics (BCLI -$0.04),
  • Verastem (VSTM -$0.02),
  • Voyager Therapeutics (VYGR -$0.02),

Closing Flat:

3 – Applied Genetic Technologies (AGTC), Biostage (BSTG), bluebird bio (BLUE) and 1 - Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

  • Friday closed positive with 23 incliners, 8 decliners, 3 flats and 1 acquired
  • Thursday closed positive with 27 incliner, 7 decliners and 1 acquired
  • Wednesday closed negative with 8 incliner, 26 decliners and 1 acquired
  • Tuesday closed negative with 7 incliners, 25 decliners, 2 flats and 1 acquired
  • Monday (2/21) was a holiday, President’s Day 

 

The BOTTOM LINE: The cell and gene therapy sector extend few gains but our universe is still positive.

The move came after new economic data showed U.S. personal spending rose more than expected in January, even accounting for a surge in inflation.

I think the biggest factor right now is the Fed and the Russian incursion into Ukraine which may make the Fed policies less aggressive.

Investors are watching earnings reports this today; as many of those reporting TODAY are showing a positive share pricing.

Q4 and end-of-year earnings are gaming than even I thought.

Earnings’ reporting:

·         Fate therapeutics, Monday, 2/28

·         BioLife Solutions (BLFS), Monday, 2/28

·         Regenxbio (RGNX), Tuesday, 3/1

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.